In a nod to increasing manufacturing in the state and around the country, Johnson & Johnson announced it will make manufacturing, research and development, and technology investments of more than $55 billion in the U.S. over the next four years.
This represents a 25% increase in investment compared to the previous four years and builds upon the company’s already elevated U.S. investment levels resulting from the passage of the 2017 Tax Cuts & Jobs Act.
“Today’s announcements accelerate our nearly 140-year legacy as an American innovation engine tackling the world’s toughest healthcare challenges,” Chair and CEO Joaquin Duato said.
The announcement came at a groundbreaking in North Carolina.
“Our increased U.S. investment begins with the ground-breaking of a high-tech facility in North Carolina that will not only add U.S.-based jobs but manufacture cutting edge medicines to treat patients in America and around the world.”
In addition to the facility in Wilson, North Carolina, the company’s increased investment in the U.S. over the next four years includes:
- Three new advanced manufacturing facilities and the expansion of several existing sites across the company’s Innovative Medicine and MedTech businesses, which will create high-paying, high-technology jobs.
- Significant investments in extensive R&D infrastructure aimed at developing lifesaving and life-changing treatments in areas such as oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery.
- Increased technology investments to help make drug discovery and development faster, support workforce training and enhance their business operations.
With its increased investment over the next four years, the company’s U.S. economic impact will build upon its already estimated more than $100 billion per year.
Johnson & Johnson has more manufacturing facilities in the U.S. than in any other country and is a leading investor in American innovation and R&D.
